Ronapreve, a combination medicine used for the treatment and prevention of COVID-19, has recently been signed off for use on at risk patients outside of the hospital.
This treatment uses antibodies to help fight of the Covid 19 virus. It has been approved for outpatients with Covid 19 and the potential to develop serious problems, so long as they exceed 12 years of age and don’t need oxygen therapy.
“With today's approval, we hope countries in the European Union will accelerate their adoption of this formidable tool to reduce the burden of COVID-19“
The European Medicines Agency (EMA) decided that the antibody therapy is also applicable for Covid 19 prevention.
Stella Kyriakides, the commissioner for Health and Food Safety, said “While the EU has one of the highest vaccination rates in the world, people will continue to fall ill and be in need of safe and effective treatments to fight infection and improve prospects not only of a faster recovery, but also of survival. The progression of the pandemic across the EU shows how fragile the situations still is and how important it is that COVID-19 patients have access to safe and effective treatments.”
The EMA is looking at six other medicines that potentially “could receive authorisation soon”, providing they prove high quality, safe, and beneficial.
President and chief scientific officer at Regeneron, Dr George Yancopoulos, said that “With today's approval, we hope countries in the European Union will accelerate their adoption of this formidable tool to reduce the burden of COVID-19. For non-hospitalised infected individuals, our antibody cocktail was shown to reduce the risk of hospitalization or death by 70%, and in the prevention setting it reduced the risk of symptomatic infections by 82%.”
Roche is the company who is mainly in control of the manufacturing and distribution of Ronapreve outside the US. Together, Regeneron and Roche have asked for EMA to accept their proposal in regard to financing Covid 19 treatment costs for people who have ended up in hospital.
The treatment has already been signed off in Japan, with conditional agreements being made in the UK and Australia. Over 40 countries have approved it for use in emergencies and on a temporary basis during the Covid 19 pandemic.See all the latest jobs in Science